231V1 needed to reach 4)23UM enterprise value in 5 years
DACARI CIAPI I AL LL,
EFTA00506128
Maji Therapeutics
■ What Is It?
A unique and patented method for preventing ... Oncolytic
Reagents agent
Introduced I_
ntroduced
ipatient
Cell Activation Incubator Infusion
Preparation
DACARI CIAPI I AL LL,
EFTA00506145
ConcentRx
Clinical studies (e.g. Dendreon, Juno) have unequivocally
shown that combining ... value in 18 months.
$25M need to reach $300M enterprise value in 4 years.
DACARI CAPI I AL LL,
EFTA00506149
Summary
• Investment opportunities identified
• 4 projects teed